Newsroom

Sorted by: Latest
-

I nuovi dati ECCO mostrano che infliximab sottocutaneo (SC) (Remsima ™ SC) è efficace nella ripresa e nel mantenimento del controllo della malattia dopo una sospensione della terapia farmacologica

INCHEON, Corea del Sud--(BUSINESS WIRE)--Celltrion, Inc. oggi ha annunciato nuovi dati derivanti da un'analisi post-hoc degli studi registrativi LIBERTY (LIBERTY-CD e LIBERTY-UC), che dimostrano che l’infliximab sottocutaneo (SC) ha ripristinato e mantenuto la risposta nella maggior parte dei pazienti con malattia di Crohn (MC) e colite ulcerosa (CU) con efficacia, sicurezza e persistenza sostenute fino alla Settimana 102.1 I dati saranno presentati in formato poster al 21o Congresso dell'ECCO...
-

Neue ECCO-Daten zeigen, dass subkutanes Infliximab (Remsima™ SC) nach einer Therapieunterbrechung die Krankheitskontrolle wirksam wiederherstellt und aufrechterhält

INCHEON, Südkorea--(BUSINESS WIRE)--Celltrion, Inc. gab heute neue Daten aus einer Post-hoc-Analyse der zulassungsrelevanten LIBERTY-Studien (LIBERTY-CD und LIBERTY-UC) bekannt, die zeigen, dass subkutanes Infliximab bei den meisten Patienten mit Morbus Crohn (MC) und Colitis ulcerosa (Cu) Krankheitskontrolle wiederherstellte und aufrechterhielt, mit anhaltender Wirksamkeit, Sicherheit und Persistenz bis zur Woche 102.1 Die Daten werden als Posterpräsentation auf dem 21. Kongress der European C...
-

New ECCO data show subcutaneous (SC) infliximab (Remsima™  SC) effectively recaptures and maintains disease control after drug holiday

INCHEON, South Korea--(BUSINESS WIRE)--Celltrion, Inc. today announced new data from a post-hoc analysis of the pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC), showing that subcutaneous (SC) infliximab restored and maintained response in most Crohn’s disease (CD) and ulcerative colitis (UC) patients with sustained efficacy, safety, and persistence through to Week 102.1 The data will be presented as a poster presentation at the 21st Congress of the European Crohn’s and Colitis Organisation...
-

De nouvelles données ECCO montrent que l’infliximab sous-cutané (SC) (Remsima™ SC) permet de reprendre et de maintenir efficacement le contrôle de la maladie après une interruption du traitement

INCHEON, Corée du Sud--(BUSINESS WIRE)--Celltrion, Inc. a annoncé aujourd’hui de nouvelles données issues d’une analyse post hoc des études pivots LIBERTY (LIBERTY-CD et LIBERTY-UC), montrant que l’infliximab sous-cutané (SC) a restauré et maintenu la réponse chez la plupart des patients atteints de la maladie de Crohn (MC) et de colite ulcéreuse (CU) avec une efficacité, une sécurité et une persistance soutenues jusqu’à la semaine 102.1 Les données seront présentées sous forme d’affiche lors d...
-

Los nuevos datos de ECCO muestran que el infliximab subcutáneo (SC) (Remsima™ SC) permite recuperar y mantener eficazmente el control de la enfermedad tras una interrupción del tratamiento

INCHEON, Corea del Sur--(BUSINESS WIRE)--Celltrion, Inc. acaba de anunciar nuevos datos de un análisis post hoc de los estudios fundamentales LIBERTY (LIBERTY-CD y LIBERTY-UC), en los que se recoge que el infliximab subcutáneo (SC) restableció y mantuvo la respuesta en la mayoría de los pacientes con enfermedad de Crohn (EC) y colitis ulcerosa (CU) con eficacia, seguridad y persistencia sostenidas hasta la semana 102.1 Los datos se presentarán en un póster en el 21 Congreso de la Organización E...
-

ATLAS FUNDING 2023 -1 PLC UK Regulatory Announcement: FRN Variable Rate Fix

LONDON--(BUSINESS WIRE)--  Re: ATLAS FUNDING 2023 -1 PLC GBP 10,132,000.00 MATURING: 20-Jan-2061 ISIN: XS2601488773 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 20-Jan-2026 TO 20-Feb-2026 HAS BEEN FIXED AT 6.48 PCT DAY BASIS: ACTUAL/365(FIX) INTEREST PAYABLE VALUE 20-Feb-2026 WILL AMOUNT TO: GBP 58,713.67 PER GBP 10,666,000.00 DENOMINATION  ...
-

Citibank UK Regulatory Announcement: FRN Variable Rate Fix

LONDON--(BUSINESS WIRE)--  Re: Atlas Funding 2024-1 PLC GBP 7,695,000.00 MATURING: 20-Sep-2061 ISIN: XS2819820288 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 20-Jan-2026 TO 20-Feb-2026 HAS BEEN FIXED AT 5.93 PCT DAY BASIS: ACTUAL/365(FIX) INTEREST PAYABLE VALUE 20-Feb-2026 WILL AMOUNT TO: GBP 40,763.57 PER GBP 8,091,818.35 DENOMINATION  ...
-

Citibank UK Regulatory Announcement: FRN Variable Rate Fix

LONDON--(BUSINESS WIRE)--  Re: ATLAS FUNDING 2025-1 PLC GBP 4,752,000.00 MATURING: 20-Jul-2062 ISIN: XS3037719138 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 20-Jan-2026 TO 20-Feb-2026 HAS BEEN FIXED AT 7.73 PCT DAY BASIS: ACTUAL/365(FIX) INTEREST PAYABLE VALUE 20-Feb-2026 WILL AMOUNT TO: GBP 31,203.51 PER GBP 4,752,000.00 DENOMINATION  ...
-

Citibank UK Regulatory Announcement: FRN Variable Rate Fix

LONDON--(BUSINESS WIRE)--  Re: Atlas Funding 2024-1 PLC GBP 15,390,000.00 MATURING: 20-Sep-2061 ISIN: XS2819820106 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 20-Jan-2026 TO 20-Feb-2026 HAS BEEN FIXED AT 5.28 PCT DAY BASIS: ACTUAL/365(FIX) INTEREST PAYABLE VALUE 20-Feb-2026 WILL AMOUNT TO: GBP 72,592.88 PER GBP 16,183,636.70 DENOMINATION  ...
-

Citibank UK Regulatory Announcement: FRN Variable Rate Fix

LONDON--(BUSINESS WIRE)--  Re: Atlas Funding 2025-2 plc GBP 18,810,000.00 MATURING: 20-Jul-2067 ISIN: XS3212016284 PLEASE BE ADVISED THAT THE INTEREST RATE FOR THE PERIOD 11-Nov-2025 TO 20-Feb-2026 HAS BEEN FIXED AT 4.96 PCT DAY BASIS: ACTUAL/365(FIX) INTEREST PAYABLE VALUE 20-Feb-2026 WILL AMOUNT TO: GBP 271,885.14 PER GBP 19,800,000.00 DENOMINATION  ...